Format

Send to

Choose Destination
See comment in PubMed Commons below
Adv Med Sci. 2014 Sep;59(2):256-60. doi: 10.1016/j.advms.2014.03.003. Epub 2014 Jun 10.

Aliskiren attenuates oxidative stress and improves tubular status in non-diabetic patients with chronic kidney disease-Placebo controlled, randomized, cross-over study.

Author information

1
Department of Occupational and Internal Medicine, Medical University of Gdansk, Gdansk, Poland. Electronic address: mrenke@gumed.edu.pl.
2
Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Gdansk, Poland.
3
Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland.
4
Department of Clinical Nutrition and Laboratory Diagnostics, Medical University of Gdansk, Gdansk, Poland.
5
Department of Occupational and Internal Medicine, Medical University of Gdansk, Gdansk, Poland.

Abstract

PURPOSE:

Pharmacological inhibition of the renin-angiotensin-aldosteron system (RAAS) may have a beneficial impact on proteinuria and chronic kidney diseases (CKD) progression. Despite recent progress by means of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), there is still no optimal therapy which can stop progression of the nephropathy. Recently introduced aliskiren is the first orally bioavailable direct renin inhibitor approved for the treatment of hypertension. The purpose was to evaluate the extent of oxidative stress and tubular injury after the direct renin inhibitor, aliskiren compared with placebo and perindopril in patients with non-diabetic chronic kidney disease (NDCKD).

MATERIAL/METHODS:

A randomized, double-blind, cross-over trial was performed in 14 patients receiving 300mg aliskiren, 10mg perindopril and placebo in random order. The end point was a change in the urinary excretion of N-acetyl-β-D-glucosaminidase (NAG) and α1-microglobulin (α1m) and 15-F(2α)-isoprostane.

RESULTS:

Aliskiren reduced excretion of 15-F(2α)-isoprostane (p=0.03) and α1m (p=0.01) as compared to placebo. There were no differences between aliskiren and perindopril in this regard. NAG urine excretion did not change after aliskiren and perindopril.

CONCLUSIONS:

Aliskiren attenuates oxidative stress and may improve functional status of tubules in patients with NDCKD.

KEYWORDS:

Aliskiren; Chronic kidney disease; Kidney; Oxidative stress; Tubular injury

PMID:
25105662
DOI:
10.1016/j.advms.2014.03.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center